Host |
Mouse |
Klon |
KH95 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil, Breast Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse |
Lokalisation |
Nucleus |
E2F1 Transcription factor
|
Diagnostic Biosystems |
KH95 |
1 ml |
Concentrate |
RUO |
MOB381 |
-
|
Host |
Mouse |
Klon |
KH95 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil, Breast Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse |
Lokalisation |
Nucleus |
E2F1 Transcription factor
|
Diagnostic Biosystems |
KH95 |
0.1 ml |
Concentrate |
RUO |
MOB381-01 |
-
|
Host |
Mouse |
Klon |
KH95 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil, Breast Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse |
Lokalisation |
Nucleus |
E2F1 Transcription factor
|
Diagnostic Biosystems |
KH95 |
0.5 ml |
Concentrate |
RUO |
MOB381-05 |
-
|
Host |
Rabbit |
Klon |
SP84 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung squamous cell carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
A synthetic peptide corresponding to C-terminus of human EGFR protein |
Lokalisation |
Cell Membrane |
EGFR
|
Zytomed Systems GmbH |
SP84 |
0.5 ml |
Concentrate |
RUO |
505-3842 |
-
|
Host |
Rabbit |
Klon |
SP84 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung squamous cell carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
A synthetic peptide corresponding to C-terminus of human EGFR protein |
Lokalisation |
Cell Membrane |
EGFR
|
Zytomed Systems GmbH |
SP84 |
1 ml |
Concentrate |
RUO |
505-3844 |
-
|
Host |
Mouse |
Klon |
2-1E1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Fast Enzyme or Pepsin |
Positivkontrolle |
Squamous cell carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Purified protein |
Lokalisation |
Cell membrane |
EGFR
|
Zytomed Systems GmbH |
2-1E1 |
0.5 ml |
Concentrate |
RUO |
MSK014-05 |
-
|
Host |
Rabbit |
Klon |
ZR16 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human EGFR protein (around aa 344-492) |
Lokalisation |
Membranous |
EGFR
|
Zeta Corporation |
ZR16 |
1 ml |
Concentrate |
CE/IVD |
Z2743RL |
-
|
Host |
Rabbit |
Klon |
ZR16 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human EGFR protein (around aa 344-492) |
Lokalisation |
Membranous |
EGFR
|
Zeta Corporation |
ZR16 |
7 ml |
Concentrate |
CE/IVD |
Z2743RP |
-
|
Host |
Rabbit |
Klon |
ZR16 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human EGFR protein (around aa 344-492) |
Lokalisation |
Membranous |
EGFR
|
Zeta Corporation |
ZR16 |
0.5 ml |
Concentrate |
CE/IVD |
Z2743RS |
-
|
Host |
Rabbit |
Klon |
ZR16 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant fragment of human EGFR protein (around aa 344-492) |
Lokalisation |
Membranous |
EGFR
|
Zeta Corporation |
ZR16 |
0.1 ml |
Concentrate |
CE/IVD |
Z2743RT |
-
|
Host |
Rabbit |
Klon |
SP111 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lung Carcinoma with E745-A750 Deletion |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
E746-A750del specific |
Lokalisation |
Cell membrane, Cytoplasm |
EGFR (E746-A750del)
|
Zytomed Systems GmbH |
SP111 |
0.5 ml |
Concentrate |
RUO |
505-4112 |
-
|
Host |
Rabbit |
Klon |
SP111 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lung Carcinoma with E745-A750 Deletion |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
E746-A750del specific |
Lokalisation |
Cell membrane, Cytoplasm |
EGFR (E746-A750del)
|
Zytomed Systems GmbH |
SP111 |
1 ml |
Concentrate |
RUO |
505-4114 |
-
|
Host |
Rat |
Klon |
ICR10 |
Format |
Lyophilised |
Methode |
FL |
Isotyp |
Rat IgG2a |
Verdünnung |
Extracellular domain of human EGF-receptor from head and neck carcinoma |
EGFr (Epidermal Growth Factor Receptor) - PE
|
Zytomed Systems GmbH |
ICR10 |
100 Tests |
Lyophilised |
RUO |
605-0021E |
-
|
Host |
Rabbit |
Klon |
SP125 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lung Carcinoma with L858R Mutationetion |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic EGFR peptide with L858R mutation |
Lokalisation |
Cell membrane, Cytoplasm |
EGFR (L858R)
|
Zytomed Systems GmbH |
SP125 |
0.5 ml |
Concentrate |
RUO |
505-4252 |
-
|
Host |
Rabbit |
Klon |
SP125 |
Format |
Concentrate |
Methode |
P, WB |
Vorbehandlung |
EDTA |
Positivkontrolle |
Lung Carcinoma with L858R Mutationetion |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic EGFR peptide with L858R mutation |
Lokalisation |
Cell membrane, Cytoplasm |
EGFR (L858R)
|
Zytomed Systems GmbH |
SP125 |
1 ml |
Concentrate |
RUO |
505-4254 |
-
|
Host |
Rabbit |
Klon |
EP774Y |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Squamous carcinoma, colon cancer |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell membrane, cytoplasmic |
EGFR (phosphorylated)
|
Biocare Medical |
EP774Y |
6 ml |
Ready-to-use |
CE/IVD |
API300AA |
-
|
Host |
Rabbit |
Klon |
EP774Y |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Diva modified Citrate pH 6.2 |
Positivkontrolle |
Squamous carcinoma, colon cancer |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cell membrane, cytoplasmic |
EGFR (phosphorylated)
|
Biocare Medical |
EP774Y |
6 ml |
Ready-to-use |
RUO |
PME300AA |
-
|
Host |
Mouse |
Klon |
BA-4 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Trypsin |
Positivkontrolle |
Heart |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Connective Tissue |
Elastin
|
Diagnostic Biosystems |
BA-4 |
1 ml |
Concentrate |
CE/IVD |
MOB230 |
-
|
Host |
Mouse |
Klon |
BA-4 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Trypsin |
Positivkontrolle |
Heart |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Connective Tissue |
Elastin
|
Diagnostic Biosystems |
BA-4 |
0.1 ml |
Concentrate |
CE/IVD |
MOB230-01 |
-
|
Host |
Mouse |
Klon |
BA-4 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Trypsin |
Positivkontrolle |
Heart |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Connective Tissue |
Elastin
|
Diagnostic Biosystems |
BA-4 |
0.5 ml |
Concentrate |
CE/IVD |
MOB230-05 |
-
|
Host |
Mouse |
Klon |
BA-4 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Trypsin |
Positivkontrolle |
Heart |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Connective Tissue |
Elastin
|
Diagnostic Biosystems |
BA-4 |
6 ml |
Ready-to-use |
CE/IVD |
PDM300 |
-
|
Host |
Mouse |
Klon |
BA-4 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Trypsin |
Positivkontrolle |
Heart |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Connective Tissue |
Elastin
|
Diagnostic Biosystems |
BA-4 |
25 ml |
Ready-to-use |
CE/IVD |
PDM300-25 |
-
|
Host |
Mouse |
Klon |
E29 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast or colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Delipidated extract of human milk fat globule membranes |
Lokalisation |
Cytoplasm and Cell membrane |
EMA
|
Zeta Corporation |
E29 |
1.0 ml |
Concentrate |
CE/IVD |
Z2048ML |
-
|
Host |
Mouse |
Klon |
E29 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast or colon carcinoma. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Delipidated extract of human milk fat globule membranes |
Lokalisation |
Cytoplasm and Cell membrane |
EMA
|
Zeta Corporation |
E29 |
7 ml |
Ready-to-use |
CE/IVD |
Z2048MP |
-
|
Host |
Mouse |
Klon |
E29 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast or colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Delipidated extract of human milk fat globule membranes |
Lokalisation |
Cytoplasm and Cell membrane |
EMA
|
Zeta Corporation |
E29 |
0.5 ml |
Concentrate |
CE/IVD |
Z2048MS |
-
|
Host |
Mouse |
Klon |
E29 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Breast or colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Delipidated extract of human milk fat globule membranes |
Lokalisation |
Cytoplasm and Cell membrane |
EMA
|
Zeta Corporation |
E29 |
0.1 ml |
Concentrate |
CE/IVD |
Z2048MT |
-
|
Host |
Mouse |
Klon |
E29 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Enzyme |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Cytoplasm, Cell Membrane |
EMA (Epithelial Membrane Antigen)
|
Diagnostic Biosystems |
E29 |
1 ml |
Concentrate |
CE/IVD |
MOB401 |
-
|
Host |
Mouse |
Klon |
E29 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Enzyme |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Cytoplasm, Cell Membrane |
EMA (Epithelial Membrane Antigen)
|
Diagnostic Biosystems |
E29 |
0.1 ml |
Concentrate |
CE/IVD |
MOB401-01 |
-
|
Host |
Mouse |
Klon |
E29 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Enzyme |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG2a kappa |
Lokalisation |
Cytoplasm, Cell Membrane |
EMA (Epithelial Membrane Antigen)
|
Diagnostic Biosystems |
E29 |
0.5 ml |
Concentrate |
CE/IVD |
MOB401-05 |
-
|
Host |
Mouse |
Klon |
MIL11 |
Format |
TCS |
Methode |
F |
Verdünnung |
1:100 - 1:500 |
Isotyp |
Mouse IgE |
Verdünnung |
Plastic adherent porcine peripheral blood lymphocytes |
Endothelial Cells
|
Zytomed Systems GmbH |
MIL11 |
2 ml |
TCS |
RUO |
605-0054 |
-
|
Host |
Mouse |
Klon |
BMK-13 |
Format |
Purified |
Methode |
F, P, EL |
Vorbehandlung |
Pepsin |
Verdünnung |
1:20 - 1:50 |
Isotyp |
Mouse IgG1 |
Eosinophil Major Basic Protein
|
Zytomed Systems GmbH |
BMK-13 |
1 ml (100 µg) |
Purified |
RUO |
605-0188 |
-
|
Host |
Mouse |
Klon |
MOC-31 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Neuraminidase treated cells from a variant small cell lung carcinoma cell line |
Lokalisation |
Cell membrane |
Ep-CAM
|
Zeta Corporation |
MOC-31 |
1ml |
Concentrate |
CE/IVD |
Z2162ML |
-
|
Host |
Mouse |
Klon |
MOC-31 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Neuraminidase treated cells from a variant small cell lung carcinoma cell line |
Lokalisation |
Cell membrane |
Ep-CAM
|
Zeta Corporation |
MOC-31 |
7 ml |
Ready-to-use |
CE/IVD |
Z2162MP |
-
|
Host |
Mouse |
Klon |
MOC-31 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Neuraminidase treated cells from a variant small cell lung carcinoma cell line |
Lokalisation |
Cell membrane |
Ep-CAM
|
Zeta Corporation |
MOC-31 |
0.5 ml |
Concentrate |
CE/IVD |
Z2162MS |
-
|
Host |
Mouse |
Klon |
MOC-31 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Neuraminidase treated cells from a variant small cell lung carcinoma cell line |
Lokalisation |
Cell membrane |
Ep-CAM
|
Zeta Corporation |
MOC-31 |
0.1 ml |
Concentrate |
CE/IVD |
Z2162MT |
-
|
Host |
Mouse |
Klon |
Ber-EP4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
MCF-7 human breast carcinoma cell line. |
Lokalisation |
Cytoplasm |
Ep-CAM
|
Zeta Corporation |
Ber-EP4 |
1ml |
Concentrate |
CE/IVD |
Z2314ML |
-
|
Host |
Mouse |
Klon |
Ber-EP4 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
MCF-7 human breast carcinoma cell line. |
Lokalisation |
Cytoplasm |
Ep-CAM
|
Zeta Corporation |
Ber-EP4 |
7 ml |
Ready-to-use |
CE/IVD |
Z2314MP |
-
|
Host |
Mouse |
Klon |
Ber-EP4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
MCF-7 human breast carcinoma cell line. |
Lokalisation |
Cytoplasm |
EP-CAM
|
Zeta Corporation |
Ber-EP4 |
0.5 ml |
Concentrate |
CE/IVD |
Z2314MS |
-
|
Host |
Mouse |
Klon |
Ber-EP4 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
MCF-7 human breast carcinoma cell line. |
Lokalisation |
Cytoplasm |
EP-CAM
|
Zeta Corporation |
Ber-EP4 |
0.1 ml |
Concentrate |
CE/IVD |
Z2314MT |
-
|
Host |
Rabbit |
Klon |
ZR307 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human Ep-CAM protein |
Lokalisation |
Cell membrane |
Ep-CAM
|
Zeta Corporation |
ZR307 |
1 ml |
Concentrate |
CE/IVD |
Z2557RL |
-
|
Host |
Rabbit |
Klon |
ZR307 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human Ep-CAM protein |
Lokalisation |
Cell membrane |
Ep-CAM
|
Zeta Corporation |
ZR307 |
7 ml |
Ready-to-use |
CE/IVD |
Z2557RP |
-
|
Host |
Rabbit |
Klon |
ZR307 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human Ep-CAM protein |
Lokalisation |
Cell membrane |
Ep-CAM
|
Zeta Corporation |
ZR307 |
0.5 ml |
Concentrate |
CE/IVD |
Z2557RS |
-
|
Host |
Rabbit |
Klon |
ZR307 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human Ep-CAM protein |
Lokalisation |
Cell membrane |
Ep-CAM
|
Zeta Corporation |
ZR307 |
0.1 ml |
Concentrate |
CE/IVD |
Z2557RT |
-
|
Host |
Mouse |
Klon |
VU-1D9 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Pepsin |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
Epithelial Specific Antigen (ESA, Ep-CAM)
|
Diagnostic Biosystems |
VU-1D9 |
1 ml |
Concentrate |
CE/IVD |
MOB062 |
-
|
Host |
Mouse |
Klon |
VU-1D9 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Pepsin |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
Epithelial Specific Antigen (ESA, Ep-CAM)
|
Diagnostic Biosystems |
VU-1D9 |
0.1 ml |
Concentrate |
CE/IVD |
MOB062-01 |
-
|
Host |
Mouse |
Klon |
VU-1D9 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Pepsin |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
Epithelial Specific Antigen (ESA, Ep-CAM)
|
Diagnostic Biosystems |
VU-1D9 |
0.5 ml |
Concentrate |
CE/IVD |
MOB062-05 |
-
|
Host |
Mouse |
Klon |
Ber-EP4 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA, Trypsin or Fast Enzyme |
Positivkontrolle |
Kidney |
Verdünnung |
1:50 - 1:150 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
Epithelial Specific Antigen (ESA, Ep-CAM)
|
Diagnostic Biosystems |
Ber-EP4 |
1 ml |
Concentrate |
CE/IVD |
MOB406 |
-
|
Host |
Mouse |
Klon |
Ber-EP4 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA, Trypsin or Fast Enzyme |
Positivkontrolle |
Kidney |
Verdünnung |
1:50 - 1:150 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
Epithelial Specific Antigen (ESA, Ep-CAM)
|
Diagnostic Biosystems |
Ber-EP4 |
0.1 ml |
Concentrate |
CE/IVD |
MOB406-01 |
-
|
Host |
Mouse |
Klon |
Ber-EP4 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
EDTA, Trypsin or Fast Enzyme |
Positivkontrolle |
Kidney |
Verdünnung |
1:50 - 1:150 |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
Epithelial Specific Antigen (ESA, Ep-CAM)
|
Diagnostic Biosystems |
Ber-EP4 |
0.5 ml |
Concentrate |
CE/IVD |
MOB406-05 |
-
|
Host |
Mouse |
Klon |
VU-1D9 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Pepsin |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa |
Lokalisation |
Cell Membrane |
Epithelial Specific Antigen (ESA, Ep-CAM)
|
Diagnostic Biosystems |
VU-1D9 |
6 ml |
Ready-to-use |
CE/IVD |
PDM077 |
-
|